Dietary intakes of fat and antioxidant vitamins are predictors of
subclinical inflammation in overweight Swiss children.
Aeberli I, Molinari L, Spinas G, Lehmann R, L'allemand D, Zimmermann MB
Am J Clin Nutr. 2006 Oct ; 84(4): 748-55
BACKGROUND: In obese children, subclinical inflammation is often
present and is correlated with the metabolic syndrome. Dietary factors,
such as fatty acids and antioxidants, potentially modulate the
association between adiposity and subclinical inflammation, but few
data are available in children. OBJECTIVE: The aim of the study was to
determine whether dietary fat or antioxidant intakes influence
circulating tumor necrosis factor alpha (TNF-alpha), interleukin 6
(IL-6), C-reactive protein (CRP), and leptin concentrations in
overweight children. DESIGN: In a cross-sectional study of 6-14-y-old
normal-weight (n = 33), overweight (n = 19), and obese (n = 27) Swiss
children, nutritional intakes were assessed from two 24-h dietary
recalls and a 1-d dietary record. Percentage body fat from skinfold
thicknesses, waist-hip ratio, and blood pressure were measured. Fasting
blood samples were collected for the measurement of insulin, glucose,
HDL-cholesterol, triacylglycerol, CRP, IL-6, TNF-alpha, and leptin
concentrations. RESULTS: CRP, IL-6, and leptin increased significantly
(P < 0.02) with increasing adiposity, independent of age; TNF-alpha did
not increase. Total dietary fat and the percentage of energy from fat
were significant predictors of CRP concentration, independent of body
mass index (P < 0.05). Meat intake was a significant predictor of IL-6
and leptin, independent of body mass index (P < 0.05). Intakes of
antioxidant vitamins (vitamins E and C and beta-carotene) were
significant predictors of leptin (P < 0.05) but not of CRP, IL-6, or
TNF-alpha. CONCLUSIONS: Overweight Swiss children as young as 6 y have
elevated concentrations of inflammatory markers. Intakes of total fat
and antioxidant vitamins are determinants of subclinical inflammation
in this age group.
----------------------------------------------------------------------------------------------------------
Molecule May Drive Multiple Sclerosis-Linked Disorder
Discovery could lead to treatments for transverse myelitis and MS
WEDNESDAY, Oct. 12 (HealthDay News) -- Researchers report that a single
molecule called IL-6 is the cause of transverse myelitis (TM), an
autoimmune disease in the central nervous system that's related to
multiple sclerosis.
The study found that levels of IL-6 are dramatically elevated in the
spinal fluid of people with TM. The finding may help in the development
of treatments for both TM and multiple sclerosis.
"This is the first time a single culprit has been identified as causing
a CNS (central nervous system) autoimmune disease," researcher Dr. Adam
Kaplin, a psychiatrist and assistant professor of medicine at Johns
Hopkins University School of Medicine, said in a prepared statement.
IL-6 is a chemical messenger that immune system cells use to
communicate with each other. Most TM patients suffer a single attack,
but 15 percent to 30 percent of TM patients go on to develop full-blown
multiple sclerosis. TM usually results in permanent impairment,
including leg and arm weakness, bowel and bladder dysfunction, pain and
paralysis.
The researchers decided to investigate IL-6 because TM patients suffer
from memory impairment and depression. Previous research implicated
IL-6 in mood and concentration disorders.
The study appears in the October issue of the Journal of Clinical
Investigation.
More information
The U.S. National Institute of Neurological Disorders and Stroke has
more about transverse myelitis.
-- Robert Preidt
SOURCE: Johns Hopkins Medicine, news release, news release, Sept. 22,
2005
Last Updated: Oct. 12, 2005
Copyright © 2005 ScoutNews LLC. All rights reserved
--------------------------------------------------------------
<<snip>>
IL6-induced BBB defect precipitates iron accumulation
<<snip>>
J Neuropathol Exp Neurol. 1998 Mar;57(3):268-82. Related Articles,
Links
Abnormal iron deposition associated with lipid peroxidation in
transgenic mice expressing interleukin-6 in the brain.
Castelnau PA, Garrett RS, Palinski W, Witztum JL, Campbell IL, Powell
HC.
Department of Pathology (Neuropathology), School of Medicine,
University of California San Diego and the Veterans Affairs Research
Service, La Jolla 92093-0612, USA.
Transgenic mice, named GFAP-IL6, that express interleukin-6 in
astrocytes in the central nervous system (CNS) have a constitutive
blood-brain barrier (BBB) defect and develop a progressive
neurodegenerative disease. Based on ultrastructural observations
showing electron-dense pigment in the brain of the GFAP-IL6 mice, we
hypothesized that iron metabolism was altered in the brains of these
animals. Enhanced histochemical methods revealed abnormal iron
deposition in the cerebellum from 1 month of age that worsened with
progression of the disease. Immunohistochemical analysis of
iron-binding proteins (IBP) showed increased ferritin immunoreactivity
and a decreased signal from the transferrin receptor in symptomatic
animals. Atomic absorption spectroscopy revealed a 40% increase of
total iron concentration in the cerebellum at the symptomatic stage. In
order to obtain evidence that accumulation of this oxidizing metal was
toxic, we looked for the presence of oxidative damage. Using the MAL-2
antibody, extensive lipid peroxidation (LP) was detected in the
neocortex and the cerebellum in symptomatic animals. Ultrastructural
analysis indicated lipofuscin deposition at the sites of neuro-axonal
degeneration and abnormal iron deposition. These results suggest that
the IL6-induced BBB defect precipitates iron accumulation in the
GFAP-IL6 mouse brain and that subsequent IBP regulation mediates
protective responses. As these defenses become overwhelmed, the iron
overload seems to promote LP, which may contribute to the
neurodegeneration that ensues. This transgenic mouse model of
IL6-mediated neurodegeneration provides a unique opportunity to examine
several aspects of iron metabolism in the brain, including its entry at
the site of the BBB, its distribution through the IBP, and its
mechanisms of toxicity.
PMID: 9600219 [PubMed - indexed for MEDLINE]
--------------------------------------------------------------------------------
Evidence of involvement of leptin and IL-6 peptides in the action of
interferon-beta in secondary progressive multiple sclerosis.
Angelucci F, Mirabella M, Caggiula M, Frisullo G, Patanella K,
Sancricca C, Nociti V, Tonali PA, Batocchi AP
Peptides. 2005 Nov ; 26(11): 2289-93
Leptin is a peptide hormone which acts on cells of immune system by
influencing the production of cytokines. Serum leptin levels and
cytokine production by peripheral blood mononuclear cells (PBMC) were
measured in 18 secondary progressive multiple sclerosis (SPMS) patients
under IFN-beta-1b treatment. There were no overall effects on leptin,
interleukin-6 (IL-6), IL-10 and IL-12 p40 after 2, 6 and 12 months of
treatment. However, leptin and IL-6 decreased after 6 and 12 months of
treatment in 12 patients who did not show progression of disability.
Thus, our pilot data show that the beneficial effect of IFN-beta on
some SPMS patients might be associated with the reduced levels of
leptin and reduced IL-6 production by PBMC.
Herbivore Hypothesis
http://sites.google.com/site/herbivorehypothesis/age-related-iron-accumulation